Variable steroid receptor responses: Intrinsically disordered AF1 is the key

Molecular and Cellular Endocrinology

Volumn 376, Issue 1-2, 2013, Pages 81-84

  Simons, S Stoney ^a   Kumar, Raj ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b Geisinger Health Geisinger Commonwealth School of Medicine   (United States)

Author keywords

AF1 domain as a molecular rheostat; Intrinsically disordered domains; Selective receptor modulators (SRMs); Selectivity in controlling gene expression; Steroid receptors

Indexed keywords

AF1 PROTEIN; GLUCOCORTICOID; LIGAND; RECEPTOR SUBUNIT; STEROID HORMONE; STEROID RECEPTOR; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG POTENCY; GENE EXPRESSION; GENE INDUCTION; GENE REPRESSION; GENE TARGETING; HORMONE ACTION; HUMAN; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RESEARCH; STEROID THERAPY;

EID: 84880009342     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.06.007     Document Type: Review

References (44)

1. Altintas D.M., Shukla M.S., Goutte-Gattat D., Angelov D., Rouault J.P., Dimitrov S., Samarut J. Direct cooperation between androgen receptor and E2F1 reveals a common regulation mechanism for androgen-responsive genes in prostate cells. Mol. Endocrinol. 2012, 26:1531-1541.
2. Anbalagan M., Huderson B., Murphy L., Rowan B.G. Post-translational modifications of nuclear receptors and human disease. Nucl. Recept. Signal. 2012, 10:e001.
3. Andersen R.J., Mawji N.R., Wang J., Wang G., Haile S., Myung J.K., Watt K., Tam T., Yang Y.C., Banuelos C.A., Williams D.E., McEwan I.J., Wang Y., Sadar M.D. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010, 17:535-546.
4. Benecke A., Chambon P., Gronemeyer H. Synergy between estrogen receptor alpha activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2. EMBO 2000, 1:151-157.
5. Bevan C.L., Hoare S., Claessens F., Heery D.M., Parker M.G. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol. Cell. Biol. 1999, 19:8383-8392.
6. Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.-A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389:753-758.
7. Chen W., Rogatsky I., Garabedian M.J. MED14 and MED1 differentially regulate target-specific gene activation by the glucocorticoid receptor. Mol. Endocrinol. 2006, 20:560-572.
8. Cho S., Kagan B.L., Blackford J.A., Szapary D., Simons S.S. Glucocorticoid receptor ligand binding domain is sufficient for the modulation of glucocorticoid induction properties by homologous receptors, coactivator transcription intermediary factor 2, and Ubc9. Mol. Endocrinol. 2005, 19:290-311.
9. Choudhry M.A., Ball A., McEwan I.J. The role of the general transcription factor IIF in androgen receptor-dependent transcription. Mol. Endocrinol. 2006, 20:2052-2061.
10. Datson N.A., Polman J.A., de Jonge R.T., van Boheemen P.T., van Maanen E.M., Welten J., McEwen B.S., Meiland H.C., Meijer O.C. Specific regulatory motifs predict glucocorticoid responsiveness of hippocampal gene expression. Endocrinology 2011, 152:3749-3757.
11. Dougherty E.J., Guo C., Simons S.S., Chow C.C. Deducing the temporal order of cofactor function in ligand-regulated gene transcription: theory and experimental verification. PLoS ONE 2012, 7:e30225.
12. Dunker A.K., Uversky V.N. Signal transduction via unstructured protein conduits. Nat. Chem. Biol. 2008, 4:229-230.
13. Fischer K., Kelly S.M., Watt K., Price N.C., McEwan I.J. Conformation of the mineralocorticoid receptor N-terminal domain: evidence for induced and stable structure. Mol. Endocrinol. 2010, 24:1935-1948.
14. Frasor J., Stossi F., Danes J.M., Komm B., Lyttle C.R., Katzenellenbogen B.S. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 2004, 64:1522-1533.
15. Garza A.M., Khan S.H., Kumar R. Site-specific phosphorylation induces functionally active conformation in the intrinsically disordered N-terminal activation function (AF1) domain of the glucocorticoid receptor. Mol. Cell. Biol. 2010, 30:220-230.
16. Heemers H.V., Regan K.M., Schmidt L.J., Anderson S.K., Ballman K.V., Tindall D.J. Androgen modulation of coregulator expression in prostate cancer cells. Mol. Endocrinol. 2009, 23:572-583.
17. Hill K.K., Roemer S.C., Jones D.N., Churchill M.E., Edwards D.P. A progesterone receptor co-activator (JDP2) mediates activity through interaction with residues in the carboxyl-terminal extension of the DNA binding domain. J. Biol. Chem. 2009, 284:24415-24424.
18. Hollenberg S.M., Evans R.M. Multiple and cooperative trans-activation domains of the human glucocorticoid receptor. Cell 1988, 55:899-906.
19. Huet G., Merot Y., Percevault F., Tiffoche C., Arnal J.F., Boujrad N., Pakdel F., Metivier R., Flouriot G. Repression of the estrogen receptor-alpha transcriptional activity by the Rho/megakaryoblastic leukemia 1 signaling pathway. J. Biol. Chem. 2009, 284:33729-33739.
20. Johnson A.B., O'Malley B.W. Steroid receptor coactivators 1, 2, and 3: critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy. Mol. Cell. Endocrinol. 2012, 348:430-439.
21. Karim F.D., Thummel C.S. Temporal coordination of regulatory gene expression by the steroid hormone ecdysone. EMBO J. 1992, 11:4083-4093.
22. Kazmin D., Prytkova T., Cook C.E., Wolfinger R., Chu T.M., Beratan D., Norris J.D., Chang C.Y., McDonnell D.P. Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. Mol. Endocrinol. 2006, 20:1201-1217.
23. Khan S.H., Awasthi S., Guo C., Goswami D., Ling J., Griffin P.R., Simons S.S.J., Kumar R. Binding of the N-terminal region of coactivator TIF2 to the intrinsically disordered AF1 domain of the glucocorticoid receptor is accompanied by conformational reorganizations. J. Biol. Chem. 2012, 287:44546-44560.
24. Kim S., Brostromer E., Xing D., Jin J., Chong S., Ge H., Wang S., Gu C., Yang L., Gao Y.Q., Su X.D., Sun Y., Xie X.S. Probing allostery through DNA. Science 2013, 339:816-819.
25. Kitagawa H., Yanagisawa J., Fuse H., Ogawa S., Yogiashi Y., Okuno A., Nagasawa H., Nakajima T., Matsumoto T., Kato S. Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol. Cell. Biol. 2002, 22:3698-3706.
26. Kressler D., Hock M.B., Kralli A. Coactivators PGC-1beta and SRC-1 interact functionally to promote the agonist activity of the selective estrogen receptor modulator Tamoxifen. J. Biol. Chem. 2007, 282:26897-26907.
27. Kumar R., McEwan I.J. Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Endocr. Rev. 2012, 33:271-299.
28. Kumar R., Thompson E.B. Transactivation functions of the N-terminal domains of nuclear hormone receptors: protein folding and coactivator interactions. Mol. Endocrinol. 2003, 17:1-10.
29. McNally J.G., Muller W.G., Walker D., Wolford R., Hager G.L. The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science 2000, 287:1262-1265.
30. Meijsing S.H., Pufall M.A., So A.Y., Bates D.L., Chen L., Yamamoto K.R. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 2009, 324:407-410.
31. Metivier R., Reid G., Gannon F. Transcription in four dimensions: nuclear receptor-directed initiation of gene expression. EMBO Rep. 2006, 7:161-167.
32. Motlagh H.N., Hilser V.J. Agonism/antagonism switching in allosteric ensembles. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:4134-4139.
33. Onate S.A., Boonyaratanakornkit V., Spencer T.E., Tsai S.Y., Tsai M.-J., Edwards D.P., O'Malley B.W. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J. Biol. Chem. 1998, 273:12101-12108.
34. Ong K.M., Blackford J.A., Kagan B.L., Simons S.S., Chow C.C. A new theoretical framework for gene induction and experimental comparisons. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7107-7112.
35. Robertson S., Allie-Reid F., Berghe W.V., Visser K., Binder A., Africander D., Vismer M., De Bosscher K., Hapgood J., Haegeman G., Louw A. Abrogation of glucocorticoid receptor dimerization correlates with dissociated glucocorticoid behavior of compound a. J. Biol. Chem. 2010, 285:8061-8075.
36. Shang Y., Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002, 295:2465-2468.
37. Shiau A.K., Barstad D., Radek J.T., Meyers M.J., Nettles K.W., Katzenellenbogen B.S., Katzenellenbogen J.A., Agard D.A., Greene G.L. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Biol. 2002, 9:359-364.
38. Simons S.S. The importance of being varied in steroid receptor transactivation. TIPS 2003, 24:253-259.
39. Simons S.S. Glucocorticoid receptor co-factors as therapeutic targets. Curr. Opin. Pharmacol. 2010, 10:613-619.
40. Tian H., Mahajan M.A., Wong C.T., Habeos I., Samuels H.H. The N-terminal A/B domain of the thyroid hormone receptor-{beta}2 isoform influences ligand-dependent recruitment of co-activators to the ligand binding domain. Mol. Endocrinol. 2006, 20:2036-2051.
41. Wang D., Wang Q., Awasthi S., Simons S.S. Amino-terminal domain of TIF2 is involved in competing for corepressor binding to glucocorticoid and progesterone receptors. Biochemistry 2007, 46:8036-8049.
42. Wardell S.E., Kazmin D., McDonnell D.P. Research resource: transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes. Mol. Endocrinol. 2012, 26:1235-1248.
43. Zajchowski D.A., Kauser K., Zhu D., Webster L., Aberle S., White F.A., Liu H.L., Humm R., MacRobbie J., Ponte P., Hegele-Hartung C., Knauthe R., Fritzemeier K.H., Vergona R., Rubanyi G.M. Identification of selective estrogen receptor modulators by their gene expression fingerprints. J. Biol. Chem. 2000, 275:15885-15894.
44. Zhang Z., Sun Y., Cho Y.-W., Chow C.C., Simons S.S. PA1: a new competitive decelerator acting at more than one step to impede glucocorticoid receptor-mediated transactivation. J. Biol. Chem. 2013, 288:42-58.